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Abstract
BACKGROUND: Abiraterone acetate (AA) is licensed for treating metastatic
castration-resistant prostate cancer (mCRPC). Real-world data on oncological
outcome after AA are scarce. The current study assesses efficacy and safety of
AA in mCRPC patients previously treated with docetaxel who started treatment
during the Belgian compassionate use program (January 2011-July 2012).
PATIENTS AND METHODS: Records from 368 patients with mCRPC from
23 different Belgian hospitals who started AA 1000mg per day with 10mg
prednisone or equivalent were retrospectively reviewed (September 2013-
December 2014). Prostate-specific antigen (PSA) response (decrease≥50%),
time to PSA progression (increase>50% over PSA nadir in case of PSA response/
>25% in absence of PSA response), time to radiographic progression (on bone
scans or for soft tissue lesions using Response Evaluation Criteria In Solid
Tumors 1.1), overall survival and adverse event rate (Common Terminology
Criteria for Adverse Events v4.03) we...
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Abstract
Background: Abiraterone acetate (AA) is licensed for treating metastatic castration-resistant prostate cancer (mCRPC). Real-world data
on oncological outcome after AA are scarce. The current study assesses efﬁcacy and safety of AA in mCRPC patients previously treated
with docetaxel who started treatment during the Belgian compassionate use program (January 2011–July 2012).
Patients and methods: Records from 368 patients with mCRPC from 23 different Belgian hospitals who started AA 1000 mg per day
with 10 mg prednisone or equivalent were retrospectively reviewed (September 2013–December 2014). Prostate-speciﬁc antigen (PSA)
response (decreaseZ50%), time to PSA progression (increase450% over PSA nadir in case of PSA response/425% in absence of PSA
response), time to radiographic progression (on bone scans or for soft tissue lesions using Response Evaluation Criteria In Solid Tumors
1.1), overall survival and adverse event rate (Common Terminology Criteria for Adverse Events v4.03) were analyzed. Kaplan-Meier
statistics were applied.
Results: Overall, 92 patients (25%) had an Eastern Cooperative Oncology Group performance statusZ2. Median age was 73 years,
median PSA was 103 ng/dl. PSA response was observed in 131 patients (37.4%). Median time to PSA and radiographic progression was 4.1
months (95% CI: 3.6–4.6) and 5.8 months (5.3–6.4), respectively. Median overall survival was 15.1 months (13.6–16.6). Most common
grade 3 to 4 adverse events were anemia (13.9%), hypokalemia (7.3%), fatigue (6.8%), and pain (6.3%). Median duration of AA treatment
was 5.3 months (interquartile range: 2.8–10.3). The main study limitation is its retrospective design.
Conclusions: These real-world data on post-docetaxel AA efﬁcacy are in line with the COU-AA-301 trial. Importantly, incidence of
severe anemia and hypokalemia is up to 50% higher than reported in previous studies. r 2016 Elsevier Inc. All rights reserved.
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1. Introduction
Since 2010, several new drugs have become available for
treatment of metastatic castration-resistant prostate cancer
(mCRPC) following progression on docetaxel [1–4]. Abir-
aterone acetate (AA) was one of the ﬁrst to demonstrate
clinical efﬁcacy in its phase 3 trial, COU-AA-301 [1]. Later,
COU-AA-302 also demonstrated clinical efﬁcacy in
patients with chemotherapy-naive mCRPC [5]. AA is a
prodrug of abiraterone, a potent inhibitor of CYP17
enzymes, thus inhibiting adrenal and intratumoral androgen
synthesis. In COU-AA-301, patients on AA 1000 mg
þ prednisone 10 mg daily showed superior overall survival
(OS) compared with patients receiving placebo þ predni-
sone 10 mg daily (15.8 mo vs. 11.2 mo, respectively),
therefore achieving its goal of demonstrating superior
clinical efﬁcacy [1]. However, because of its focus on
efﬁcacy and standardized protocols for patient selection and
follow-up, its results might not necessarily translate into
efﬁcacy in daily clinical practice [6,7]. Little is known
about the real-world efﬁcacy and adverse event rate of AA.
To our knowledge only 3 studies have analyzed oncological
outcome and tolerability in a cohort of4100 patients with
mCRPC post-docetaxel outside clinical trials [8–10]. There-
fore, we retrospectively analyzed patients with mCRPC
who started AA treatment in the Belgian compassionate use
(CU) program (January 2011–July 2012). The goal of this
article is to determine oncological outcome and adverse
event rate and indirectly compare these with the active arm
of COU-AA-301. To the best of our knowledge, this article
reports results from the largest mCRPC cohort outside a
clinical trial.
2. Materials and methods
2.1. Patients
Physicians from 23 Belgian hospitals provided a list of
all consecutive patients who started AA treatment in the
Belgian CU program. A total of 368 patients were
identiﬁed. This CU program was initiated on January 1,
2011, allowing patients with docetaxel-treated mCRPC
access to AA. It closed July 31, 2012, when AA was
reimbursed for use post-docetaxel in Belgium. All patients
started AA at a dose of 1000 mg daily with 10 mg
prednisone or equivalent. Treatment was continued until
disease progression, severe toxicity, death or patient/physi-
cian’s preference. At the end of the Belgian CU program,
patients still on AA continued this treatment. After AA
start, patient follow-up was at the treating physician’s
discretion, but follow-up visits were recommended every
2 weeks for the ﬁrst 3 months and then monthly thereafter
for safety, with prostate-speciﬁc antigen (PSA) levels and
radiographic evaluation assessed every 3 months.
Data on oncological outcome, adverse events, and
previous prostate cancer (PC) treatments were retrospec-
tively retrieved from the patient ﬁle by the ﬁrst author
(C.V.P.) in 18 centers (264 patients; 71.7%) or by local data
managers in 5 centers (104 patients; 28.3%) between
September 2013 and December 2014. Data retrieved
included all available reports from clinical visits, lab
results, imaging, and date of death. Follow-up time was
deﬁned as time between start of AA and date of last follow-up
or death. PSA doubling time was calculated using the
Memorial Sloan Kettering online calculator [11]. Date of
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CRPC was deﬁned as date of PSA progression following
surgical or chemical castration therapy or anti-androgen
therapy before docetaxel. The study was approved by central
and local ethic committees (central EC UZG 2013/413).
Patients were eligible for the CU program when they had
histologically/cytologically conﬁrmed PC, received at least
1 but no more than 2 different cytotoxic chemotherapy
regimens for mCRPC with at least 1 taxane regimen and
had PC progression, deﬁned by PSA progression according
to Prostate Cancer Working Group 2 criteria [12] or by
radiographic progression in soft tissue according to
Response Evaluation Criteria in Solid Tumors criteria
version 1.1, [13] or on bone scans. Patients were to have
a serum testosterone o50 ng/dl, an Eastern Cooperative
Oncology Group (ECOG) performance status r2, hemo-
globin Z9.0 g/dl, platelet count Z100.000/μl, serum
albumin Z3.0 g/dl, serum creatinine o1.5  upper limit
of normal (ULN) or a calculated creatinine clearance Z60
ml/min and serum potassium Z3.5 mmol/l.
Patients were ineligible for the CU program if they were
previously enrolled in COU-AA-301 or COU-AA-302, had
serious or uncontrolled co-existent nonmalignant disease,
had bilirubin Z1.5  ULN or aspartate aminotransferase,
or alanine aminotransferase Z2.5  ULN, uncontrolled
hypertension, active or symptomatic viral hepatitis or
chronic liver disease, history of pituitary or adrenal dys-
function, clinically signiﬁcant heart disease, known brain
metastasis or any acute toxicities because of prior chemo-
therapy or radiotherapy that had not resolved to a grader1
according to Common Terminology Criteria for Adverse
Events.
2.2. Outcomes
Primary outcome was OS, deﬁned as time from start of
AA until death. Secondary outcomes were cancer-speciﬁc
survival (CSS), PSA response rate, time to PSA progres-
sion, time to radiographic progression and rate of adverse
events, skeletal-related events (SREs) and number of
hospitalizations during AA treatment. CSS was deﬁned as
time from start of AA until death because of PC. A PSA
response was deﬁned as a PSA decline Z50% after at least
4 weeks of AA treatment, conﬁrmed by a second PSA
decline at least 4 weeks later. Similar to COU-AA-301, for
patients whose PSA did not decrease, PSA progression was
deﬁned as a PSA increase Z25% over the baseline and an
increase Z2 ng/ml. For patients whose PSA decrea-
sed o50%, PSA progression was deﬁned as a PSA
increase Z25% above the nadir and an increase Z2
ng/ml. For PSA responders, PSA progression was deﬁned
as a PSA increase Z50% above the nadir and an increa-
se Z2 ng/ml. To allow more accurate comparison with
COU-AA-301 data, secondary calculations were made for
PSA response and time to PSA progression using only
PSA values measured at 3-monthly intervals. Radiographic
progression was deﬁned as progression by soft tissue
imaging (modiﬁed response evaluation criteria in solid
tumors criteria with a baseline lymph nodeZ2.0 cm to be
considered target lesion [13]) or by bone scan with Z2 new
lesions not consistent with tumor ﬂare. Analysis of radio-
graphic progression was restricted to patients who had
imaging (computed tomography, magnetic resonance
imaging, or bone scan) within 30 days before AA start.
The following adverse events during AA treatment were
scored according to Common Terminology Criteria for
Adverse Events version 4.03 [14]: pain, diarrhea, nausea,
vomiting, fatigue, peripheral edema, cardiac disorders
(ischemic heart disease; myocardial infarction; [supra]
ventricular tachyarrhythmias; cardiac failure; or possible
arrhythmia-related investigations, signs, and symptoms),
anemia, neutropenia, thrombocytopenia, rising liver
enzymes (aspartate aminotransferase or alanine amino-
transferase), hypokalemia and hypertension (at least 3
blood pressure measurements required). SRE was deﬁned
as any pathological bone fracture, spinal cord compres-
sion, palliative radiation to the bone or surgery to the bone
because of bone metastases.
2.3. Statistical analysis
Continuous variables are presented as median (interquar-
tile range [IQR]). Survival analyses were performed
using Kaplan-Meier statistics. Differences between catego-
rical variables were assessed using chi-square test. All
statistical analyses were performed with SPSS version
22.0 (IBM, NY). Po 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Patient characteristics and AA treatment
Patient, disease and previous treatment characteristics are
listed in Table 1. CU protocol violations included 5 (1.4%)
patients who received no previous chemotherapy, 23 (6.3%)
patients who previously received42 different chemother-
apy regimens and 9 (2.4%) patients who had an ECOG
performance status Z3 at start of AA. These patients were
included in further analysis. Median duration of AA treat-
ment was 5.3 months (IQR: 2.8–10.3). After a median
follow-up time of 13.9 months (IQR: 6.1–22.6), 334
(90.8%) patients discontinued AA, either because of
disease progression (276, 75.0%), toxicity (29, 7.9%), death
(28; 7.6%), or physician’s preference (1, 0.3%). AA treat-
ment was still ongoing in 17 (4.6%) patients, whereas data
on AA continuation were missing in 17 (4.6%) patients at
the time of evaluation. Treatment with AA was temporarily
interrupted in 15 (4.1%) patients, whereas a dose reduction
to 500 to 750 mg AA daily was performed in 13 (3.5%)
patients, all related to toxicity.
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3.2. Oncological outcome
Of all 368 patients, 283 (76.9%) died–213 (57.9%)
because of PC progression, 10 (2.7%) because of infectious
disease, 3 (0.8%) because of another malignancy, and 7
(1.9%) because of other causes. In 50 (13.6%) patients,
cause of death was unknown. Median OS and CSS from
start of AA were 15.1 months (95% CI: 13.6–16.6) and 16.8
months (95% CI: 14.6–19.0), respectively. Median OS from
date of CRPC was 42.0 months (95% CI: 34.6–49.5) (based
on 237 patients with 179 events). In 18 (4.9%) patients, no
PSA values during AA treatment were available. Of the
remaining 350 patients, 131 (37.4%) had a PSA response
(Fig. 1). PSA progression was documented in 280 (80.0%)
patients. Median time to PSA progression was 4.1 months
(95% CI: 3.6–4.6). When only using 3 monthly PSA values,
as was customary in COU-AA-301, usable PSA values
were missing in 57 (15.5%) patients. Of the remaining 311
patients, 103 (33.1%) had a PSA response and median time
to PSA progression was 6.0 months (95% CI: 5.5–6.5). In
an intention-to-treat analysis in patients with any PSA
follow-up, 29.4% (103 of 350) had a PSA response and
median time to PSA progression was 6.0 months (95% CI:
5.5–6.5). Only 212 (57.6%) patients had imaging before
AA start, of which 119 (56.1%) experienced radiographic
progression. Median time to radiographic progression was
5.8 months (95% CI: 5.3–6.4) (Fig. 2).
3.3. Adverse events
Rate of grade 3 to 4 hematological disorders (anemia,
neutropenia, and thrombocytopenia) and hypokalemia was
notably high (Table 2). Patients with an ECOG performance
statusZ2 were more susceptible to hematological disorders
and hypokalemia (all Po 0.05). Overall, 68 SREs occurred
during AA in 57 (15.5%) patients as follows: 50 cases of
palliative radiotherapy, 12 observations of spinal cord
compression, 4 cases of bone fracture, and 2 patients who
had surgery to the bone. Finally, 137 (37.3%) patients were
hospitalized at least once during AA treatment.
4. Discussion
We retrospectively assessed oncological outcome and
adverse events of AA treatment post-docetaxel in 368
patients with mCRPC from 23 hospitals during the Belgian
CU program. Although our study is limited by its retro-
spective design, our oncological results conﬁrm AA’s
efﬁcacy [1]. Regarding tolerability, however, concerns can
be raised over a surprisingly high incidence of hematolog-
ical side effects and hypokalemia. To the best of our
knowledge, this is the largest cohort of patients with taxane
pretreated mCRPC reported on in a nonclinical trial setting
(Table 3). Previously, Caffo et al. [8] retrospectively
analyzed records from 265 patients with mCRPC treated
during the Italian named patient program. Clayton et al. [9]
retrospectively analyzed 187 patients with mCRPC treated
at 5 tertiary Canadian centers. More recently, Houédé et al.
[10] retrospectively analyzed 306 patients with mCRPC
treated during the French temporary authorization for use
program. These studies reported good clinical outcome and
low adverse event rate. In a worldwide early access protocol
study in 2314 patients, Sternberg et al. [15] reported low
adverse event rate. Furthermore, Azad et al. [16] described a
cohort of 519 patients, both chemotherapy naïve and
pretreated, who received AA, but only reported on different
oncological outcome between patients with ECOGo 2 and
ECOG Z 2.
Table 1
Patient, disease and previous treatment characteristics
N ¼ 368 Missing
cases
Demographics at start AA
Age, years, median (IQR) 73 (66–77) 2
ECOG performance status, n (%) 13 (3.5)
0–1 263 (71.5)
2 83 (22.6)
3 7 (1.9)
4 2 (0.5)
Serum values at start AA, median (IQR)
Hemoglobin, g/dl 11.6 (10.2–13.0) 19
Alkaline phosphatase, U/l 142 (80–287) 36
Lactate dehydrogenase, U/l 513 (379–692) 48
Prostate-speciﬁc antigen, ng/dl 103 (34–329) 4
Time parameters at start AA, median (IQR)
Time since diagnosis, mo 77 (41–129) 45
Time since CRPC, mo 22 (11–40) 129
Time off treatment, wk 11 (4–22) 31
Disease characteristics at start AA, n (%)
Local tumor in prostate (bed) 183 (49.7) 27 (7.3)
Lymph node metastases 205 (55.7) 15 (4.1)
Bone metastases 327 (88.9) 5 (1.4)
Visceral metastases (all) 76 (20.7) 12 (3.3)
Liver metastases 32 (8.7) 12 (3.3)
Lung metastases 31 (8.4) 12 (3.3)
Disease progression 74 (20.1)
PSA only 94 (25.5)
progression on imaging 200 (54.3)
Presence of pain 250 (67.9) 16 (4.3)
Previous treatment characteristics, n (%)
Local treatment with surgery or
radiotherapy
210 (57.1) 18 (4.9)
Number of chemotherapy linesa 12 (3.3)
0 5 (1.4)
1 180 (48.9)
2 109 (29.6)
3 44 (12.0)
43 18 (4.9)
Bone protecting agent before start AA 245 (66.6) 20 (5.4)
Prior skeletal-related event 135 (36.7) 42 (11.4)
aRechallenge with a chemotherapy line previously administered was
considered as another line.
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In our series, rate of anemia (91.6% all grades, 13.9%
gradeZ3) and hypokalemia (7.3% gradeZ3) was higher
compared with COU-AA-301 (7.8% and 4.4% grade Z3,
respectively) and other reports (0.1%–4.2% and 0.4%–1.6%
respectively, Table 2) [1,8–10,15]. We have several possible
explanations. First, patients in clinical trials are generally in
Fig. 1. Maximal PSA drop during abiraterone acetate treatment. Waterfall plot depicting maximal prostate-speciﬁc antigen (PSA) response (%) for each
patient, based on the formula (PSA nadir during abiraterone acetate [AA]—PSA at start AA)/PSA at start AA. Negative values indicate a drop in PSA. All
available PSA measurements for each patient were used to determine PSA nadir. (Color version of ﬁgure is available online.)
Fig. 2. Patient outcomes. Kaplan-Meier plots depicting overall survival (A), cancer-speciﬁc survival (B), radiographic progression-free survival (C) and
prostate-speciﬁc antigen (PSA) progression-free survival (D). (Color version of ﬁgure is available online.)
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better condition than patients outside clinical trials [6]. In our
cohort, more patients had an ECOG statusZ2 (25%)
compared with COU-AA-301 (10%). These patients were
more susceptible to anemia and hypokalemia compared with
patients with an ECOG statuso2. Second, we used all
parameters available in the patient ﬁles, unlike COU-AA-301
that used time-speciﬁc parameters. With more values avail-
able, we had a higher chance of detecting abnormalities.
Third, because of ethical obligations in clinical trials, mild
adverse events may be treated more aggressively than they
would be in daily clinical practice, reducing the risk of
exacerbation and thus the number of serious adverse events
[7]. Fourth, patients in clinical trials generally demonstrate
more rigorous compliance with both anti-tumor and other
medication, reducing the chance of adherence-related side
effects [17]. These data stress the ongoing need to screen
patients for these speciﬁc side effects, especially in the ﬁrst
months of AA treatment that might allow timely intervention.
Fewer cardiac disorders were observed (0.8% gradeZ3)
compared with COU-AA-301 (5.2%) [1]. Again, this might be
explained by the different study design. Patients in
COU-AA-301 underwent a standard cardiac examination,
consisting of a multigated acquisition scan or cardiac ultra-
sonography and electrocardiography, at baseline and end-of-
study and electrocardiography every 3 months during treatment
[1]. Protocol-induced testing may lead to detection of cardiac
disorders that would otherwise have gone undetected in daily
clinical practice, where a cardiac examination is not routinely
Table 2
Adverse events recorded during AA treatment (%)
% GradeZ3 Belgian CU program COU-AA-301 [1] Sternberg et al. [15] Caffo et al. [8] Clayton et al. [9]
Paina 6.3 7.3 – – –
Diarrhea 0 1.1 – 0.4 0
Nausea 1.4 2.1 – 0.4 0
Vomiting 0.5 2.7 – 0 –
Fatigue 6.8 9.1 – 4.2 0.5
Peripheral edema 0.8 0.5 1 0.4 0
Cardiac disordersb 0.8 5.2 2.2 0 –
Anemia 13.9 7.8 1.7 4.2 0.1
Neutropenia 1.9 0.1 – 0 1.1
Thrombocytopenia 4.1 1.4 – 0.8 0
Liver enzymes 3.5 3.8 8.1 0c 0.5
Hypokalemiad 7.3 4.4 1.2 0.4 1.6
Hypertension 3.5 1.3 4.3 0.4 1.1
aPain was assessed by investigators in the Belgian compassionate use (CU) program, whereas it was scored according to the Brief Pain Inventory in
COU-AA-301.
bCardiac disorders included ischemic heart disease, myocardial infarction, supraventricular tachyarrhythmias, ventricular tachyarrhythmias, cardiac failure,
and possible arrhythmia-related investigations, signs, and symptoms.
cAny liver toxicity.
dIn the Belgian CU program at least 3 blood pressure measurements above threshold were needed to deﬁne hypertension.
Table 3
Oncological outcome with abiraterone acetate post-docetaxel as reported in literature
Background N
patients
PSA response
rate (%)
Median time to PSA
progression, mo
Median time to
radiographic
progression, mo
Overall
survival (mo)
Caffo et al. [8] Italian named patient program,
retrospective
265 50 NR NR 17
Clayton et al. [9] 5 Canadian tertiary centers,
retrospective
187 36 3.5 NR 11
Fizazi et al. [1] COU-AA-301 trial (active arm),
prospective
797 29.5 8.5 5.6 15.8
Houédé et al. [10] French temporary authorization
for use program, retrospective
306 NR NR NR 14.6
Sternberg et al. [15] Early access protocol trial in
23 countries, prospective
2314 NR 8.5 NR NR
Van Praet et al.
(current)
Belgian compassionate use
program,
retrospective
368 37.4 or 29.4a 4.1 or 6.0a 5.8 15.1
NR ¼ not reported.
aWhen using only 3-monthly PSA values.
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performed in the absence of symptoms [7]. Other AA-speciﬁc
side effects, including elevated liver enzymes, peripheral edema
and hypertension, were within expected ranges.
In our patient cohort, median OS was 15.1 months, which
is in line with COU-AA-301 (15.8 mo) and other observa-
tional studies (11–17 mo) [1,8–10]. AA post-docetaxel appears
to be similarly effective in daily clinical practice as in clinical
trials: median time to radiographic progression (5.8 mo) is
comparable with COU-AA-301 (5.6 mo) [1]. Interestingly,
PSA response rate was notably higher (37.4% vs. 29.5%),
whereas median time to PSA progression was notably shorter
(4.1 vs. 8.5 mo) compared with COU-AA-301 [1]. However,
unlike OS and radiographic progression, PSA kinetics are
difﬁcult to compare between both studies. In COU-AA-301
serum PSA was only measured at 3-monthly intervals. In our
study, we used all available PSA values at least 4 weeks after
AA start, which might more sensitively detect both PSA
response and progression. When utilizing 3-monthly PSA
measurements only, we found a PSA response rate of 29.4%
and median time to PSA progression of 6.0 months, which is
more in line with COU-AA-301. This phenomenon is con-
sistent in the literature: other studies on real-world AA
treatment restricting PSA testing to 3-monthly intervals had
longer time to PSA progression (Sternberg et al.: 8.5 mo [15])
than studies using all PSA values clinically available (Clayton
et al.: 3.5 mo) [9].
Limitations to the current analysis include its retrospective
design with inherent missing data because of incomplete
patient ﬁles and attribution bias. However, most outcomes
were based on ﬁxed data such as blood values or time points.
As only patients treated within the Belgian CU program were
included, these data might not be representative for every
patient with mCRPC treated in daily clinical practice. Notwith-
standing these limitations, this study gives important insights as
these real-world data reﬂect what clinicians can encounter
when starting a patient on AA post-docetaxel. Following COU-
AA-302, the place of AA in mCRPC treatment has shifted
upfront to chemotherapy-naive patients. It seems unlikely that
AA’s tolerability would be inferior in the pre-docetaxel comp-
ared with the post-docetaxel setting, but evaluation of its real-
world efﬁcacy pre-docetaxel remains warranted.
5. Conclusion
These real-world data on AA efﬁcacy are in line with
COU-AA-301 and other reports in the post-docetaxel
setting. Concerning tolerability, however, incidence of
severe anemia and hypokalemia is up to 50% higher than
reported in previous studies, indicating rigorous follow-up
of these patients remains important.
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